Gastrointestinal Cancers

Program Director: Ramaswamy Govindan, MD

Faculty:

Richard M. Goldberg, MD Axel Grothey, MD John L. Marshall, MD

Robert S. Mocharnuk, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

• Discuss results from multiple recently reported studies on the relationship between KRAS mutation status and response to therapy in patients with colorectal cancer, and explain the clinical implications of these results
• Summarize reported data on the efficacy of therapy combining anti–epidermal growth factor receptor and anti–vascular endothelial growth factor antibodies in colorectal cancer
• Describe reported benefits of addition of FDG-PET imaging to CT scan in patient selection for curative resection of liver metastases in colorectal cancer
• Summarize recent findings on use of gemcitabine in adjuvant treatment of pancreatic cancer

Topics covered include:

• KRAS Status as Predictor of Epidermal Growth Factor Receptor Blocker Response: Accumulating Evidence
• EVEREST: Cetuximab Dose Escalation Ineffective in Mutated-KRAS Patients
• Defective Mismatch Repair Portends Poor Response to 5-FU–Based Chemotherapy
• NSABP C-07 Update: Adjuvant Oxaliplatin Plus 5-FU/LV Improves Overall and DFS
• NSABP C-08: Safety and Tolerability of Adjuvant FOLFOX Plus Bevacizumab
• CAIRO2: In Advanced Colorectal Cancer, 2 Targeted Antibodies No Better Than 1
• Ca2+/Mg2+ as Neuroprotection From Adjuvant Oxaliplatin
• Resection of Liver Metastases: Does Adding FDG-PET to CT Improve Patient Selection?
• CONKO-001 Update: In Pancreatic Cancer, Survival Benefit Seen From Adjuvant Gemcitabine
• Conclusions